Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP14 | P50281 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039179 | 0.89 | MMP2 (0.67) | MMP2MMP9MMP14ACACBMMP1 | |
| SCHEMBL17026751 | 0.87 | MMP2 (0.56) | MMP2MMP9MMP14ACACBMMP1 | |
| SCHEMBL20878717 | 0.84 | ACACB (0.47) | ACACBMAPTKMT2ATP53MEN1 | |
| SCHEMBL20078579 | 0.83 | ACACB (0.48) | ACACBMAPTKMT2ATP53MEN1 | |
| SCHEMBL17039173 | 0.82 | MMP2 (0.55) | MMP2MMP9MMP14MMP1MMP13 | |
| SCHEMBL28346942 | 0.78 | MMP2 (0.58) | MMP2MMP9MMP14ACACBMMP1 | |
| SCHEMBL20078580 | 0.76 | ACACB (0.47) | MMP2MMP9MMP14ACACBMAPT | |
| SCHEMBL14679174 | 0.76 | MAPT (0.66) | ACACBMAPTKMT2ATP53POLB | |
| SCHEMBL17026740 | 0.76 | MMP2 (0.74) | MMP2MMP9MMP14ACACBMMP1 | |
| SCHEMBL17039174 | 0.74 | ACACB (0.50) | ACACBMAPTKMT2ATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951035-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-07-06 | — | — | US | disclosed |
| US-9604957-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604957-B2 | Selective matrix metalloproteinase inhibitors | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170015647-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015647-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2015127302-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190685-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | MMP14, MMP9, MMP13 | MMP2 14/4885MMP9 2/4885MMP14 1/4885 |
| US-20170015647-A1 | SELECTIVE MATRIX METALLOPROTEINASE INHIBITORS | MMP14, MMP9, MMP13 | MMP2 14/4885MMP9 2/4885MMP14 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.